ATMPs in Germany - Beqvez®

👉 Being the second of the latest two authorized ATMPs, Beqvez was not launched in Germany, yet.

Beqvez (previously Durveqtix, active substance: fidanacogene elaparvovec) was authorized in July 2024 for treatment of hemophilia B. In addition to Hemgenix, it is second gene therapy for treatment of hemophilia B. The efficacy of Beqvez was evaluated in the pivotal single-arm trial C0371002 (N=45). Beqvez was not yet launched in Germany and thus, is not available.

Therefore, no🏆German HTA started and no 💵 price was listed.

💡 Once launched, Beqvez would be subject to the ATMP Quality Assurance Guideline. Like Casgevy, the German HTA body currently examines Beqvez to be subject to routine practice data collection.